This trial is evaluating whether ABBV-514 will improve 7 primary outcomes in patients with Lung Cancer. Measurement will happen over the course of Up to 2 Years.
This trial requires 136 total participants across 5 different treatment groups
This trial involves 5 different treatments. ABBV-514 is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Abbv-514 improved the quality of life of patients with advanced oral cancers, compared with standard care alone. This effect was independent of age, gender, and performance status." - Anonymous Online Contributor
"Oral SCC was seen in approximately 1 in 97,000 adults per year in the United States during 1996–1995. These rates were slightly higher among men at 1 in 107, and lower among African Americans at 1 in 111. Although the overall incidence of oral SCC increased from 1980 to 1995, there was no significant increase in the number of new cases of oral SCC detected annually during this time period. The reason for this disparity between incidence and detection remains unclear." - Anonymous Online Contributor
"Recent findings show that patients have a positive attitude towards clinical trials. Patient's willingness to participate can depend on how they perceive risks related to clinical trials. The main reasons why patients would not want to participate were lack of information about clinical trials, misunderstandings regarding their purpose, and emotional distress related to risk perception. As a result, and considering our findings, we think that patients' attitudes toward clinical trials are good." - Anonymous Online Contributor
"Oral SCC are highly metastatic tumors. With current therapies, ~40% of patients with advanced disease achieve complete remission. curative resection may improve survival but does not prevent recurrence. It is important to recognize when curative surgery may offer the best chance of long-term survival and to continue these patients on postoperative surveillance so that early detection and intervention can minimize the morbidity and mortality associated with SCC." - Anonymous Online Contributor
"There are no additional ABBV-514 trial enrollments underway at any time. The Phase I and II studies were completed successfully. Findings from a recent study of these studies will be reported soon.\n" - Anonymous Online Contributor
"ABBV-514 is an immunostimulatory peptide that promotes CD8+ T-cell responses against O-glycan antigens expressed on human leukemia and gut tumors. This peptide also appears to induce greater tumor regression when given following initial chemotherapy than after subsequent surgery." - Anonymous Online Contributor
"The most commonly used treatments for oral squamous cell carcinoma were surgery (63%), radiation therapy (33%), and combined chemotherapy (3%). Because of the wide range of treatments for oral squamous cell carcinoma, it is important that patients receive all the information they need to make an informed decision about their treatment options." - Anonymous Online Contributor
"Abbv-514 has shown some activity in treating oral squamous cell carcinomas. The mechanism of action of the drug seems to be inhibition of telomerase activity. Further studies are needed to explore whether this effect is related to abbv-514's anticancer activities." - Anonymous Online Contributor
"Results from large multi-institutional studies indicate that there is no improvement over previous data in terms of overall survival and disease-free survival for OSCC patients treated with concurrent chemoradiotherapy (CRT). In addition, the quality of life remains poor. However, improvements in local control were seen in select subgroups of patients, especially those who received CRT alone." - Anonymous Online Contributor
"Oral cancer occurs more frequently in men than women at all ages. The mean age at diagnosis for OSCC was 70 years, with a range of 51 years to 94 years. In a recent study, the average age of presentation of OSCC was 73 years. Findings from a recent study provides additional evidence that smoking increases the risk of developing oral cancer." - Anonymous Online Contributor
"The 5-year survival rate for patients diagnosed with oral cancer was 58%. The strongest predictors of outcome were patient age and socioeconomic status. Patients who had undergone radiotherapy received a significantly better survival outcome than those who did not." - Anonymous Online Contributor